These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 24342473)
21. Performance of an alternative laboratory-based algorithm for HIV diagnosis in a high-risk population. Delaney KP; Heffelfinger JD; Wesolowski LG; Owen SM; Meyer WA; Kennedy S; Uniyal A; Kerndt PR; Branson BM J Clin Virol; 2011 Dec; 52 Suppl 1():S5-10. PubMed ID: 22019251 [TBL] [Abstract][Full Text] [Related]
22. A multicenter performance evaluation of the DPP(®) HIV-1/2 assay for the detection of HIV antibodies in various HIV testing algorithms. Cappello JM; Gunasekera A; Gunasekera D; Esfandiari J; Ippolito T J Clin Virol; 2013 Dec; 58 Suppl 1():e59-64. PubMed ID: 24342478 [TBL] [Abstract][Full Text] [Related]
23. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008. Patel P; Mackellar D; Simmons P; Uniyal A; Gallagher K; Bennett B; Sullivan TJ; Kowalski A; Parker MM; LaLota M; Kerndt P; Sullivan PS; Arch Intern Med; 2010 Jan; 170(1):66-74. PubMed ID: 20065201 [TBL] [Abstract][Full Text] [Related]
24. Performance evaluation of the Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA, a 4th generation HIV assay for the simultaneous detection of HIV p24 antigen and antibodies to HIV-1 (groups M and O) and HIV-2 in human serum or plasma. Bentsen C; McLaughlin L; Mitchell E; Ferrera C; Liska S; Myers R; Peel S; Swenson P; Gadelle S; Shriver MK J Clin Virol; 2011 Dec; 52 Suppl 1():S57-61. PubMed ID: 21995929 [TBL] [Abstract][Full Text] [Related]
25. Comparative performance of the Geenius™ HIV-1/HIV-2 supplemental test in Florida's public health testing population. Fordan S; Bennett B; Lee M; Crowe S J Clin Virol; 2017 Jun; 91():79-83. PubMed ID: 28434810 [TBL] [Abstract][Full Text] [Related]
26. HIV single staging algorithm: integration and maximization of resources by reducing time between HIV diagnosis and treatment. Bennett B; Hardy B; Fordan S; Haddock-Morilla L; Rowlinson MC; Crowe S J Clin Virol; 2013 Dec; 58 Suppl 1():e34-7. PubMed ID: 23993447 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of an alternative supplemental testing strategy for HIV diagnosis by retrospective analysis of clinical HIV testing data. Styer LM; Sullivan TJ; Parker MM J Clin Virol; 2011 Dec; 52 Suppl 1():S35-40. PubMed ID: 22018662 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab Combo Assay. Chavez P; Wesolowski L; Patel P; Delaney K; Owen SM J Clin Virol; 2011 Dec; 52 Suppl 1():S51-5. PubMed ID: 21983253 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of Xpert HIV-1 Qual assay for resolution of HIV-1 infection in samples with negative or indeterminate Geenius HIV-1/2 results. Michaeli M; Wax M; Gozlan Y; Rakovsky A; Mendelson E; Mor O J Clin Virol; 2016 Mar; 76():1-3. PubMed ID: 26761545 [TBL] [Abstract][Full Text] [Related]
30. Comparative evaluation of Aptima HIV-1 Qualitative RNA assay performance using plasma and serum specimens from persons with established HIV-1 infection. Ethridge SF; Wesolowski LG; Nasrullah M; Kennedy MS; Delaney KP; Candal D; Owen SM J Clin Virol; 2011 Dec; 52 Suppl 1():S63-6. PubMed ID: 21995932 [TBL] [Abstract][Full Text] [Related]
31. Multi-centre field evaluation of the performance of the Trinity Biotech Uni-Gold HIV 1/2 rapid test as a first-line screening assay for gay and bisexual men compared with 4th generation laboratory immunoassays. Keen P; Conway DP; Cunningham P; McNulty A; Couldwell DL; Davies SC; Smith DE; Gray J; Holt M; O'Connor CC; Read P; Callander D; Prestage G; Guy R J Clin Virol; 2017 Jan; 86():46-51. PubMed ID: 27914286 [TBL] [Abstract][Full Text] [Related]
32. Performance comparison of the 4th generation Bio-Rad Laboratories GS HIV Combo Ag/Ab EIA on the EVOLIS™ automated system versus Abbott ARCHITECT HIV Ag/Ab Combo, Ortho Anti-HIV 1+2 EIA on Vitros ECi and Siemens HIV-1/O/2 enhanced on Advia Centaur. Mitchell EO; Stewart G; Bajzik O; Ferret M; Bentsen C; Shriver MK J Clin Virol; 2013 Dec; 58 Suppl 1():e79-84. PubMed ID: 24342482 [TBL] [Abstract][Full Text] [Related]
33. Comparison of 4th-Generation HIV Antigen/Antibody Combination Assay With 3rd-Generation HIV Antibody Assays for the Occurrence of False-Positive and False-Negative Results. Muthukumar A; Alatoom A; Burns S; Ashmore J; Kim A; Emerson B; Bannister E; Ansari MQ Lab Med; 2015; 46(2):84-9; quiz e28-9. PubMed ID: 25918186 [TBL] [Abstract][Full Text] [Related]
34. Clinical performance of the Multispot HIV-1/HIV-2 rapid test to correctly differentiate HIV-2 from HIV-1 infection in screening algorithms using third and fourth generation assays and to identify cross reactivity with the HIV-1 Western Blot. Ramos EM; Harb S; Dragavon J; Coombs RW J Clin Virol; 2013 Dec; 58 Suppl 1(0 1):e104-7. PubMed ID: 24342468 [TBL] [Abstract][Full Text] [Related]
35. Use of rapid HIV assays as supplemental tests in specimens with repeatedly reactive screening immunoassay results not confirmed by HIV-1 Western blot. Wesolowski LG; Delaney KP; Meyer WA; Blatt AJ; Bennett B; Chavez P; Granade TC; Owen M J Clin Virol; 2013 Sep; 58(1):240-4. PubMed ID: 23838670 [TBL] [Abstract][Full Text] [Related]
36. Would CLSI M53-A have helped in the diagnosis of HIV in Canada? Results of the performance of Canadian laboratories participating in a recent NLHRS proficiency testing panel containing HIV-1 antigen positive (antibody negative) and HIV-2 samples. Kadivar K; Malloch L; Adonsou-Hoyi Y; Ng D; Lavoie S; Pulido K; Kim J J Clin Virol; 2013 Sep; 58(1):303-5. PubMed ID: 23890809 [TBL] [Abstract][Full Text] [Related]
37. Finding those at risk: acute HIV infection in Newark, NJ. Martin EG; Salaru G; Mohammed D; Coombs RW; Paul SM; Cadoff EM J Clin Virol; 2013 Dec; 58 Suppl 1(0 1):e24-8. PubMed ID: 23953941 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of Performance of Two Rapid Tests for Detection of HIV-1 and -2 in High- and Low-Prevalence Populations in Nigeria. Manak MM; Njoku OS; Shutt A; Malia J; Jagodzinski LL; Milazzo M; Suleiman A; Ogundeji AA; Nelson R; Ayemoba OR; O'Connell RJ; Singer DE; Michael NL; Peel SA J Clin Microbiol; 2015 Nov; 53(11):3501-6. PubMed ID: 26311857 [TBL] [Abstract][Full Text] [Related]
39. Three Years of Shared Service HIV Nucleic Acid Testing for Public Health Laboratories: Worthwhile for HIV-1 but Not for HIV-2. Styer LM; Gaynor AM; Parker MM; Bennett SB; Wesolowski LG; Ethridge S; Chavez PR; Sullivan TJ; Fordan S; Wroblewski K Sex Transm Dis; 2020 May; 47(5S Suppl 1):S8-S12. PubMed ID: 31876868 [TBL] [Abstract][Full Text] [Related]
40. Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm. Chang M; Wong AJ; Raugi DN; Smith RA; Seilie AM; Ortega JP; Bogusz KM; Sall F; Ba S; Seydi M; Gottlieb GS; Coombs RW J Clin Virol; 2017 Jan; 86():56-61. PubMed ID: 27951466 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]